WSH Incorporates Drug Approval Dates from BioMedTracker for Pharma Traders
The dataset will provide all relevant and potentially market-moving event dates around drug trials and approvals.
The vendor rolled out the data into Enchilada as a "soft launch" earlier this month, following a beta test period in January with a few hedge funds and other clients to whom WSH provides XML feeds.
In addition to FDA PDUFA (Prescription Drug User Fee Act) dates, BioMedTracker also provides WSH with other relevant information, such as the date when a drug enters review by the FDA, expected approval date plus any changes to that expected date, and the final notice of approval or denial for both
Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.
To access these options, along with all other subscription benefits, please contact info@waterstechnology.com or view our subscription options here: https://subscriptions.waterstechnology.com/subscribe
You are currently unable to print this content. Please contact info@waterstechnology.com to find out more.
You are currently unable to copy this content. Please contact info@waterstechnology.com to find out more.
Copyright Infopro Digital Limited. All rights reserved.
As outlined in our terms and conditions, https://www.infopro-digital.com/terms-and-conditions/subscriptions/ (point 2.4), printing is limited to a single copy.
If you would like to purchase additional rights please email info@waterstechnology.com
Copyright Infopro Digital Limited. All rights reserved.
You may share this content using our article tools. As outlined in our terms and conditions, https://www.infopro-digital.com/terms-and-conditions/subscriptions/ (clause 2.4), an Authorised User may only make one copy of the materials for their own personal use. You must also comply with the restrictions in clause 2.5.
If you would like to purchase additional rights please email info@waterstechnology.com
More on Emerging Technologies
Waters Wavelength Ep. 331: Cresting Wave’s Bill Murphy
Bill Murphy, Blackstone’s former CTO, joins to discuss that much-discussed MIT study on AI projects failing and factors executives should consider as the technology continues to evolves.
FactSet adds MarketAxess CP+ data, LSEG files dismissal, BNY’s new AI lab, and more
The Waters Cooler: Synthetic data for LLM training, Dora confusion, GenAI’s ‘blind spots,’ and our 9/11 remembrance in this week’s news roundup.
Chief investment officers persist with GenAI tools despite ‘blind spots’
Trading heads from JP Morgan, UBS, and M&G Investments explained why their firms were bullish on GenAI, even as “replicability and reproducibility” challenges persist.
Wall Street hesitates on synthetic data as AI push gathers steam
Deutsche Bank and JP Morgan have differing opinions on the use of synthetic data to train LLMs.
A Q&A with H2O’s tech chief on reducing GenAI noise
Timothée Consigny says the key to GenAI experimentation rests in leveraging the expertise of portfolio managers “to curate smaller and more relevant datasets.”
Etrading wins UK bond tape, R3 debuts new lab, TNS buys Radianz, and more
The Waters Cooler: The Swiss release an LLM, overnight trading strays further from reach, and the private markets frenzy continues in this week’s news roundup.
AI fails for many reasons but succeeds for few
Firms hoping to achieve ROI on their AI efforts must focus on data, partnerships, and scale—but a fundamental roadblock remains.
Waters Wavelength Ep. 330: AI hot takes
It’s Shen and Reb this week talking about AI and the landscape for fintech partnerships.